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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER113Improving Survival of Patients With OHCAGordon A. Ewy, Arthur B. Sanders
Survival of patients with out-of-hospital cardiac arrest (OHCA) was essentially unchanged
from the mid-1970s to the mid-2000s, averaging 7.6% for all OHCA and 17.7% for OHCA
due to ventricular fibrillation (VF). Ewy and Sanders utilized animal models to study the
hemodynamics of resuscitation from cardiac arrest and test alternative therapies such as
compression only cardiopulmonary resuscitation, passive ventilation rather than intubation,
and compressions prior to and after defibrillation. The therapies that appeared useful were
then incorporated into clinical practice using a continuous quality improvement program
which resulted in significant improvements in survival for OHCA. The authors review their
efforts and call on others to adopt the model of continuous quality improvement to further
increase survival rates for OHCA.Commentary: Thomas D. Rea, page 119VIEWPOINT VIEWPOINT121Viewpoint: Is Hospital Admission for Heart Failure Really Necessary?Sean P. Collins, Peter S. Pang, Gregg C. Fonarow, Clyde W. Yancy, Robert O. Bonow, Mihai Gheorghiade
Only a minority of emergency department (ED) patients with heart failure (HF) are severely
ill as a result of pulmonary edema, myocardial ischemia or cardiogenic shock. The majority of
patients need only decongestion with diuretics. Collins and colleagues argue that up to 50%
of ED patients with HF could be safely discharged after a brief period of observation, thus
avoiding unnecessary admissions, and minimizing readmissions. Observation unit (OU)
management may be beneficial for low- and intermediate-risk HF patients as continued
treatment and more precise risk-stratification may ensue. The authors propose a clinical trial
of OU management versus inpatient admission for low risk HF patients.
Commentary: Akshay S. Desai, Lynne W. Stevenson, page 127(continued on page A-30)
JANUARY 15, 2013 (continued) A-30CLINICAL RESEARCHiCARDIOVASCULAR RISK131Meta-Analysis Confirms Benefits of ACE-Is and ARBs in Patients Without HFGianluigi Savarese, Pierluigi Costanzo, John George Franklin Cleland, Enrico Vassallo, Donatella Ruggiero,
Giuseppe Rosano, Pasquale Perrone-Filard
Savarese and colleagues performed a meta-analysis to assess the effects of angiotensin-
converting-enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) on the
rates of cardiovascular (CV) death, myocardial infarction (MI) and stroke in high-risk patients
without heart failure (HF). Twenty-six randomized trials comparing ARBs or ACE-Is versus
placebo in 108,212 patients without HF were collected in a meta-analysis. ACE-Is
significantly reduced the risk of the composite endpoint as well as the individual endpoints of
MI, stroke, all-cause death, new-onset HF, and new-onset diabetes. ARBs significantly
reduced the risk of the composite outcome, stroke, and new onset DM, but not the other
individual endpoints. These results confirm the benefits of ACE-Is in patients at high CV
risk without HF, and that ARBs should be considered in patients in whom ACE-Is cannot
be used.CARDIOVASCULAR RISK1439p21.3 CAD Risk Genotype Not Mediated Through Interferon-Naif A. M. Almontashiri, Meng Fan, Brian L. M. Cheng, Hsiao-Huei Chen, Robert Roberts,
Alexandre F. R. Stewart
The mechanism whereby a common genetic variant at chromosome 9p21.3 confers increased
risk for coronary artery disease (CAD) remains uncertain. Almontashiri and colleagues tested
whether the 9p21 genotype modifies the response to interferon- on the expression of p16
(encoded by CDKN2A) and p15 (encoded by CDKN2B) as recently reported. Several cell
lines including vascular cells were genotyped for the 9p21.3 locus, treated with interferon-
and analyzed by immunoblot. In all cells tested, except human umbilical vein endothelial cells
where expression was not modulated by interferon-, regardless of 9p21.3 genotype,
nterferon- increased the expression of p16 and p15. These results counter the previous
reports that the 9p21.3 risk genotype affects the activation of cyclin-dependent kinase
inhibitors p15 and p16 by interferon-.(continued on page A-32)
JANUARY 15, 2013 (continued) A-32CARDIOVASCULAR RISK148Cardiovascular Event Reduction Versus NOD During Atorvastatin TherapyDavid D. Waters, Jennifer E. Ho, S. Matthijs Boekholdt, David A. DeMicco, John J. P. Kastelein,
Michael Messig, Andrei Breazna, Terje R. Pedersen
Waters and colleagues previously reported that 4r factors independently predict new-onset
diabetes (NOD) in patients treated with a statin: FBG 100 mg/dl, fasting triglycerides
150 mg/dl, BMI 30 kg/m2, and a history of hypertension. For this study, the incidence
of NOD was calculated using data from the TNT and IDEAL trials which randomized
patients to high dose atorvastatin or low dose atorvastatin 10 mg or simvastatin 20 to 40 mg.
For subjects with 0 to 1 NOD risk factors, NOD developed in 3.2% of subjects in the
atorvastatin 80 mg group and in 3.3% in the combined low-dose cohorts. In subjects with
2 to 4 NOD risk factors, NOD developed in 14.3% in the atorvastatin 80 mg group and in
11.9% in the lower dose groups for a hazard ratio of 1.2. Cardiovascular events were
significantly reduced with atorvastatin 80 mg in both NOD risk groups.HEART FAILURE153Readmissions Following Implantation of Axial Flow LVADTal Hasin, Yariv Marmor, Walter Kremers, Yan Topilsky, Cathy J. Severson, John A. Schirger,
Barry A. Boilson, Alfredo L. Clavell, Richard J. Rodeheffer, Robert P. Frantz, Brooks S. Edwards,
Naveen L. Pereira, John M. Stulak, Lyle Joyce, Richard Daly, Soon J. Park, Sudhir S. Kushwaha
Hasin and colleagues reviewed their records to determine the occurrence and causes of
readmissions after implantation of axial flow left ventricular assist devices (LVAD). From a
cohort of 115 patients, there were 224 readmissions in 83 patients. The overall readmission
rate was 1.6 per patient/year follow-up and was higher during the first 6 months. Leading
causes of readmission were bleeding (mostly for gastrointestinal bleed), cardiac (most for heart
failure or arrhythmia), infections and thrombosis. These data show fairly low rates of hospital
readmission rates after axial flow LVAD implantation.(continued on page A-33)
JANUARY 15, 2013 (continued) A-33HEART RHYTHM DISORDERS164Identifying Families With Early Repolarization SyndromeJean-Baptiste Gourraud, Solena Le Scouarnec, Frederic Sacher, Stéphanie Chatel, Nicolas Derval,
Vincent Portero, Pascal Chavernac, Juan E Sandoval, Philippe Mabo, Richard Redon, Jean-Jacques Schott,
Hervé Le Marec, Michel Haïssaguerre, Vincent Probst
The aim of this study was to identify families affected by early repolarization syndrome (ERS)
and to determine if there is a genetic mode of transmission. Four families affected by ERS
were studied from 22 cases of sudden cardiac death. ERS was defined as a distinct J-wave in
at least 2 consecutive leads and at least 1-mm amplitude. In the 4 families, the prevalence of
ERS was 56%, 34%, 61% and 33%, and the patterns suggests an autosomal dominant mode
of inheritance. The Valsalva maneuver, which is postulated to decrease heart rate and increase
the likelihood of finding ERS, increased the J-wave amplitude for 17 out of 20 affected
patients, and revealed an ERS pattern in 17 relatives who otherwise did not manifest ERS.
These findings show that ERS can be inherited through autosomal dominant transmission
and should be considered as a real inherited arrhythmia syndrome.Editorial Comment: Andrew D. Krahn, Manoj N. Obeyesekere, page 173CARDIAC IMAGING176Prognostic Value of Stress Myocardial Perfusion Positron Emission TomographySharmila Dorbala, Marcelo F. Di Carli, Rob S. Beanlands, Michael E. Merhige, Brent A. Williams,
Emir Veledar, Benjamin J. W. Chow, James K. Min, Michael J. Pencina, Daniel S. Berman, Leslee J. Shaw
The primary objective of this multicenter registry was to determine the prognostic value of
positron emission tomography (PET) myocardial perfusion imaging (MPI). 7,061 patients
from 4 centers underwent a clinically indicated rest/stress rubidium-82 PET MPI with a
median follow-up of 2.2 years. The primary outcome of this study was cardiac death and the
secondary outcome was all-cause death. Risk-adjusted hazard of cardiac death increased with
each 10% abnormal myocardium. Addition of myocardium ischemic and scarred to clinical
information improved the C-statistic and net reclassification index for cardiac death. These
results confirm that PET MPI provides powerful and incremental risk stratification compared
to traditional coronary risk factors.
Editorial Comment: Paul Schoenhagen, Rory Hachamovitch, page 185(continued on page A-34)
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FBIOMARKERS187Elevated Levels of BNP and Troponin Identify Patients With LVH at High Risk of CHFIan J. Neeland, Mark H. Drazner, Jarett D. Berry, Colby R. Ayers, Christopher deFilippi, Stephen L. Seliger,
Vijay Nambi, Darren K. McGuire, Torbjørn Omland, James A. de Lemos
Neeland and colleagues sought to determine if serum levels of cardiac troponin T (cTnT),
and/or N-terminal pro-B type natriuretic peptide (NT-proBNP) can identify which
asymptomatic individuals with left ventricular hypertrophy (LVH) are at higher risk for heart
failure (HF) and death. Subjects without clinical HF or chronic kidney disease underwent
measurement of LV mass by MRI, cTnT by highly sensitive assay, and NT-proBNP.
Although only 6% of the study population had LVH with cTnT and/or NT-proBNP,
hese individuals accounted for approximately 40% of all HF or cardiovascular death events.
he crude hazard ratio (HR) for the primary outcome was 22.6 for LVH cTnT and 15.5
or LVH NT-proBNP. Elevations in cardiac biomarkers identify those patients with
VH at high risk for progression to HF or cardiovascular death.EXPEDITED PUBLICATION
194ffect of Serelaxin on Cardiac, Renal and Hepatic
Biomarkers in the RELAX-AHF Development ProgramMarco Metra, Gad Cotter, Beth A. Davison, G. Michael Felker, Gerasimos Filippatos, Barry H. Greenberg,
Piotr Ponikowski, Elaine Unemori, Adriaan A. Voors, Kirkwood F. Adams, JR, Maria Dorobantu,
iliana Grinfeld, Guillaume Jondeau, Alon Marmor, Josep Masip, Peter S. Pang, Karl Werdan,
argaret F. Prescott, Christopher Edwards, Samuel L. Teichman, Angelo Trapani, Christopher A. Bush,
ajnish Saini, Christoph Schumacher, Thomas Severin, John R. Teerlink, for the Relaxin in Acute Heart
ailure Investigators
Serelaxin is a recombinant form of human relaxin-2, a naturally occurring peptide hormone
which mediates the physiological cardiovascular and renal adaptations that occur during
pregnancy. In the RELAX-AHF Trial, serelaxin significantly reduced 180 day mortality
compared to placebo in patients hospitalized with acute heart failure (AHF). Metra and
colleagues analyzed the effects of serelaxin on serum biomarkers of organ damage, as well as
signs and symptoms of congestion resolution. Changes in markers of cardiac (hs-TnT), renal
(creatinine and cystatin-C) and hepatic (AST and ALT) damage, and of decongestion
(NT-pro-BNP), were associated with 180-day mortality and were improved with serelaxin
administration. These results further support the hypothesis that serelaxin safely improves
AHF congestion.
